Skip to main content
. Author manuscript; available in PMC: 2020 Nov 3.
Published in final edited form as: Semin Neurol. 2020 Sep 9;40(5):523–539. doi: 10.1055/s-0040-1713846

Figure 3. Designs of clinical trials for neurogenic orthostatic hypotension.

Figure 3.

The gold standard design for clinical trials of nOH remains the double-blind randomized parallel-group placebo-controlled trial. This design allows for easier interpretation of the findings and eliminates several known sources of bias. Other designs, however, are used frequently in clinical trials of nOH, including the crossover design and the withdrawal design (see text for details).